LGND logo

LIGAND PHARMACEUTICALS

LGNDNASDAQ
πŸ† #1017 by market capEarnings Nov 4US Equity
$288.83β–Ό $6.79 (βˆ’2.35%)
Market closed Β· at close
1hβ€”
24hβ–Ό 2.4%
7dβ–Ό 4.4%
14dβ–² 0.2%
30dβ–Ό 6.9%
1yβ–² 89.5%
🏦Market Cap
$5.79B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+51.2%
High Growth
πŸ“ŠGross Margin
95.3%
High
πŸ’΅FCF Margin
44.9%
Strong
βš–οΈP/S Ratio
21.6x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$284.97 – $292.71
52-Week Range
$137.14 – $326.63
Volume
$5.31B
Avg Volume
$5.00B
Shares Outstanding
20.0M
Next Earnings
Sep 9, 2026

Fundamentals Snapshot

Annual Revenue
$268M
Last Q Revenue
$64M
P/E Ratio
38.7
P/S Ratio
21.6x
EPS (TTM)
$7.42
Dividend Yield
β€”

Why Investors Own LGND

  • βœ“High-growth profile β€” revenue up +39.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 35% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$268Mβ–² +39.9% YoY
Gross Margin (TTM)
34.8%β–² +2.9% YoY
Operating Income (TTM)
$83Mβ–² +39.9% YoY
Free Cash Flow (TTM)
$54Mβ–² +39.9% YoY

About LIGAND PHARMACEUTICALS

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$383.82
β–² +32.9% Upside
High Target$479.33
Low Target$286.28
Based on 15 analysts

Latest News & Updates